Sung Ji Nam
Stock Analyst at Scotiabank
(3.20)
# 1,147
Out of 4,761 analysts
68
Total ratings
50%
Success rate
1.64%
Average return
Main Sectors:
Stocks Rated by Sung Ji Nam
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| ADPT Adaptive Biotechnologies | Maintains: Sector Outperform | $10 → $12 | $8.27 | +45.10% | 2 | Feb 13, 2025 | |
| WAT Waters | Upgrades: Sector Outperform | $430 → $450 | $374.82 | +20.06% | 2 | Feb 13, 2025 | |
| TECH Bio-Techne | Maintains: Sector Outperform | $88 → $90 | $64.92 | +38.63% | 2 | Feb 6, 2025 | |
| TWST Twist Bioscience | Maintains: Sector Outperform | $54 → $62 | $41.31 | +50.08% | 5 | Feb 4, 2025 | |
| TMO Thermo Fisher Scientific | Maintains: Sector Perform | $605 → $650 | $532.55 | +22.05% | 13 | Feb 3, 2025 | |
| DHR Danaher | Initiates: Sector Perform | $265 | $210.23 | +26.05% | 1 | Dec 23, 2024 | |
| PACB Pacific Biosciences of California | Maintains: Sector Outperform | $7 → $6 | $1.54 | +289.61% | 4 | Nov 11, 2024 | |
| VCYT Veracyte | Maintains: Sector Outperform | $40 → $44 | $39.18 | +12.30% | 4 | Nov 8, 2024 | |
| CSTL Castle Biosciences | Maintains: Sector Outperform | $37 → $44 | $25.75 | +70.87% | 5 | Nov 6, 2024 | |
| CDNA CareDx | Maintains: Buy | $40 → $35 | $22.29 | +57.02% | 4 | Nov 5, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Sector Outperform | $3 | $0.88 | +240.14% | 1 | Sep 16, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Sector Perform | $360 → $60 | $5.36 | +1,019.40% | 5 | Aug 28, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Sector Outperform | $176 → $164 | $94.20 | +74.10% | 9 | Aug 15, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Sector Outperform | $29 → $34 | $14.18 | +139.77% | 2 | Aug 13, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Sector Outperform | $70 | $49.26 | +42.10% | 1 | Jun 27, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Assumes: Buy | $6 | $7.45 | -19.46% | 2 | Jun 29, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Sector Outperform | $36 | $42.87 | -16.03% | 3 | Jan 5, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | n/a | $16.46 | - | 3 | Nov 24, 2020 |
Adaptive Biotechnologies
Feb 13, 2025
Maintains: Sector Outperform
Price Target: $10 → $12
Current: $8.27
Upside: +45.10%
Waters
Feb 13, 2025
Upgrades: Sector Outperform
Price Target: $430 → $450
Current: $374.82
Upside: +20.06%
Bio-Techne
Feb 6, 2025
Maintains: Sector Outperform
Price Target: $88 → $90
Current: $64.92
Upside: +38.63%
Twist Bioscience
Feb 4, 2025
Maintains: Sector Outperform
Price Target: $54 → $62
Current: $41.31
Upside: +50.08%
Thermo Fisher Scientific
Feb 3, 2025
Maintains: Sector Perform
Price Target: $605 → $650
Current: $532.55
Upside: +22.05%
Danaher
Dec 23, 2024
Initiates: Sector Perform
Price Target: $265
Current: $210.23
Upside: +26.05%
Pacific Biosciences of California
Nov 11, 2024
Maintains: Sector Outperform
Price Target: $7 → $6
Current: $1.54
Upside: +289.61%
Veracyte
Nov 8, 2024
Maintains: Sector Outperform
Price Target: $40 → $44
Current: $39.18
Upside: +12.30%
Castle Biosciences
Nov 6, 2024
Maintains: Sector Outperform
Price Target: $37 → $44
Current: $25.75
Upside: +70.87%
CareDx
Nov 5, 2024
Maintains: Buy
Price Target: $40 → $35
Current: $22.29
Upside: +57.02%
Sep 16, 2024
Initiates: Sector Outperform
Price Target: $3
Current: $0.88
Upside: +240.14%
Aug 28, 2024
Downgrades: Sector Perform
Price Target: $360 → $60
Current: $5.36
Upside: +1,019.40%
Aug 15, 2024
Maintains: Sector Outperform
Price Target: $176 → $164
Current: $94.20
Upside: +74.10%
Aug 13, 2024
Maintains: Sector Outperform
Price Target: $29 → $34
Current: $14.18
Upside: +139.77%
Jun 27, 2024
Initiates: Sector Outperform
Price Target: $70
Current: $49.26
Upside: +42.10%
Jun 29, 2023
Assumes: Buy
Price Target: $6
Current: $7.45
Upside: -19.46%
Jan 5, 2023
Initiates: Sector Outperform
Price Target: $36
Current: $42.87
Upside: -16.03%
Nov 24, 2020
Downgrades: Neutral
Price Target: n/a
Current: $16.46
Upside: -